From: CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
NIND | CIS | MS | LNB | OIND | |
---|---|---|---|---|---|
Demographic data | |||||
Samples | 20 | 30 | 20 | 8 | 30 |
Samples for Immuno-phenotyping CSF/Blood | 19/13 | 30/28 | 20/15 | 8/3 | 30/24 |
Age (years) | 32 (18 to 77) | 31 (17 to 51) | 38 (18 to 69) | 57 (37 to 78) | 41 (18 to 73) |
Sex female/male | 10/10 | 15/15 | 11/9 | 6/2 | 11/19 |
Phase of disease (Number of patients) | Acutea symptoms (20) | Acutea relapse (27), remission (3) | Acutea relapse (15), remission (5) | Acutea (6), chronicb (2) | Acutea (22), remission (2), unknown (6) |
CSF parametes | |||||
CSF cell count per μl | 2 (1 to 5) | 7 (1 to 29) | 7 (0 to 81) | 106 (9 to 280) | 33 (2 to 512) |
QAlbumin | 5 (3.0 to 9.6) | 5 (3.1 to 10.1) | 5 (3.3 to 7.5) | 12 (6.0 to 25.9) | 8 (3.7 to 55.5) |
Intrathecal IgG production | 0/20 | 17/30 | 13/18 | 7/8 | 10/29 |
Intrathecal IgA production | 0/20 | 0/30 | 2/18 | 5/8 | 9/29 |
Intrathecal IgM production | 0/20 | 4/30 | 5/18 | 6/8 | 6/29 |
OCBs (+/-) | 0/20 | (25/0)c | (19/1) | (6/2) | (13/17) |
Impairment blood-CSF barrier | 2/18 | 8/30 | 3/20 | 6/8 | 21/30 |